Northwest Biotherapeutics (NWBO) Cash from Financing Activities (2010 - 2026)

Northwest Biotherapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $9.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 21.51% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $46.8 million (down 17.06% YoY), while the FY2025 annual figure was $49.3 million, down 13.13% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $9.2 million, down from $13.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $17.1 million in Q2 2024, with the low at $3.9 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $12.1 million (2024), against an average of $12.4 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 63.57% in 2022, then surged 220.97% in 2023.
• Northwest Biotherapeutics' Cash from Financing Activities stood at $11.4 million in 2022, then grew by 26.99% to $14.4 million in 2023, then climbed by 10.59% to $15.9 million in 2024, then decreased by 14.77% to $13.6 million in 2025, then sank by 32.23% to $9.2 million in 2026.
• Business Quant data shows NWBO's Cash from Financing Activities at $9.2 million in Q1 2026, $13.6 million in Q4 2025, and $11.6 million in Q3 2025.